MOMETASONE FUROATE- mometasone furoate cream

United States - English - NLM (National Library of Medicine)

Buy It Now

Active ingredient:
MOMETASONE FUROATE (UNII: 04201GDN4R) (MOMETASONE - UNII:8HR4QJ6DW8)
Available from:
NORTHSTAR RX LLC
Administration route:
TOPICAL
Prescription type:
PRESCRIPTION DRUG
Therapeutic indications:
Mometasone Furoate Cream USP, 0.1% contains mometasone furoate, USP for topical use. Mometasone furoate, USP is a synthetic corticosteroid with anti-inflammatory activity. Chemically, mometasone furoate, USP is 9α,21-dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-diene-3,20-dione 17-(2-furoate), with the empirical formula C27 H30 Cl2 O6 , a molecular weight of 521.43 and the following structural formula: Mometasone furoate, USP is a white to off-white powder, soluble in acetone and methylene chloride. Each gram of Mometasone Furoate Cream USP, 0.1% contains: 1 mg mometasone furoate, USP in a cream base of aluminum starch octenyl succinate (Dry-Flo Plus (Pure)), hexylene glycol, phospholipon 90 H, phosphoric acid, purified water, titanium dioxide, white petrolatum, and white wax.
Product summary:
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Avoid excessive heat.
Authorization status:
Abbreviated New Drug Application
Authorization number:
16714-974-01, 16714-974-02

MOMETASONE FUROATE- mometasone furoate cream

NORTHSTAR RX LLC

----------

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use MOMETASONE FUROATE CREAM safely

and effectively. See full prescribing information for MOMETASONE FUROATE CREAM.

MOMETASONE FUROATE Cream, 0.1% for topical use

Initial U.S. Approval: 1987

RECENT MAJOR CHANGES

Warnings and Precautions

INDICATIONS AND USAGE

Mometasone furoate cream, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations

of corticosteroid-responsive dermatoses in patients ≥ 2 years of age. (1)

DOSAGE AND ADMINISTRATION

DOSAGE FORMS AND STRENGTHS

CONTRAINDICATIONS

Mometasone furoate cream, 0.1% is contraindicated in those patients with a history of hypersensitivity to any of the

components in the preparation. (4)

WARNINGS AND PRECAUTIONS

ADVERSE REACTIONS

Most common adverse reactions are: burning, pruritus, and skin atrophy. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Northstar Rx LLC at 1800-206-7821 or FDA at 1-800-

FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.

Revised: 5/2019

FULL PRESCRIBING INFORMATION: CONTENTS*

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

Ophthalmic Adverse Reactions (5.2) 05/2018

Apply a thin film to the affected skin areas once daily. (2)

Discontinue therapy when control is achieved. (2)

If no improvement is seen within 2 weeks, reassess diagnosis. (2)

Do not use with occlusive dressings unless directed by a physician. (2)

Cream, 0.1%. (3)

Reversible HPA axis suppression with the potential for glucocorticosteroid insufficiency after withdrawal of treatment,

Cushing’s syndrome, and hyperglycemia may occur due to systemic absorption. Patients applying a topical steroid to

a large surface area or to areas under occlusion should be evaluated periodically for evidence of HPA axis

suppression. Modify use should HPA axis suppression develop. (5.1, 8.4)

Pediatric patients may be more susceptible to systemic toxicity. (5.1, 8.4)

May increase the risk of cataracts and glaucoma. If visual symptoms occur, consider referral to an ophthalmologist.

(5.2)

5 WARNINGS AND PRECAUTIONS

5.1 Effects on Endocrine System

5.2 Ophthalmic Adverse Reactions

5.3 Allergic Contact Dermatitis

5.4 Concomitant Skin Infections

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

17 PATIENT COUNSELING INFORMATION

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION

Sections or subsections omitted from the full prescribing information are not listed.

Mometasone furoate cream, 0.1% is a corticosteroid indicated for the relief of the inflammatory

and pruritic manifestations of corticosteroid-responsive dermatoses in patients 2 years of age or

older.

Apply a thin film of mometasone furoate cream, 0.1% to the affected skin areas once daily.

Mometasone furoate cream, 0.1% may be used in pediatric patients 2 years of age or older. Since

safety and efficacy of mometasone furoate cream, 0.1% have not been established in pediatric

patients below 2 years of age; use in this age group is not recommended [see Warnings and

Precautions (5.1) and Use in Specific Populations (8.4)].

Therapy should be discontinued when control is achieved. If no improvement is seen within 2

weeks, reassessment of diagnosis may be necessary [see Warnings and Precautions (5.1)].

Do not use mometasone furoate cream, 0.1% with occlusive dressings unless directed by a

physician. Do not apply mometasone furoate cream, 0.1% in the diaper area if the patient still

requires diapers or plastic pants, as these garments may constitute occlusive dressing.

Avoid contact with eyes. Wash hands after each application.

3 DOSAGE FORMS AND STRENGTHS

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Effects on Endocrine System

5.2 Ophthalmic Adverse Reactions

5.3 Allergic Contact Dermatitis

Avoid use on the face, groin, or axillae.

Mometasone furoate cream, 0.1% is for topical use only. It is not for oral, ophthalmic, or

intravaginal use.

Cream, 0.1%. Each gram of Mometasone Furoate Cream USP, 0.1% contains 1 mg of mometasone

furoate, USP in a white to off-white, uniform and smooth cream.

Mometasone furoate cream, 0.1% is contraindicated in those patients with a history of

hypersensitivity to any of the components in the preparation.

Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-

adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency. This may

occur during treatment or after withdrawal of treatment. Manifestations of Cushing’s syndrome,

hyperglycemia, and glucosuria can also be produced in some patients by systemic absorption of

topical corticosteroids while on treatment. Factors that predispose a patient using a topical

corticosteroid to HPA axis suppression include the use of high-potency steroids, large treatment

surface areas, prolonged use, use of occlusive dressings, altered skin barrier, liver failure and

young age.

Because of the potential for systemic absorption, use of topical corticosteroids may require that

patients be periodically evaluated for HPA axis suppression. This may be done by using the

adrenocorticotropic hormone (ACTH) stimulation test.

In a study evaluating the effects of mometasone furoate cream on the HPA axis, 15 grams were

applied twice daily for 7 days to six adult subjects with psoriasis or atopic dermatitis. The results

show that the drug caused a slight lowering of adrenal corticosteroid secretion.

If HPA axis suppression is noted, an attempt should be made to gradually withdraw the drug, to

reduce the frequency of application, or to substitute a less potent corticosteroid. Recovery of

HPA axis function is generally prompt upon discontinuation of topical corticosteroids.

Infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring

supplemental systemic corticosteroids.

Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their

larger skin surface to body mass ratios [see Use in Specific Populations (8.4)].

Use of topical corticosteroids may increase the risk of posterior subcapsular cataracts and

glaucoma. Cataracts and glaucoma have been reported in postmarketing experience with the use of

topical corticosteroids, including the topical mometasone products [see Adverse Reactions (6.2)].

Avoid contact of mometasone furoate cream with eyes. Advise patients to report any visual

symptoms and consider referral to an ophthalmologist for evaluation.

5.4 Concomitant Skin Infections

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

6.2 Postmarketing Experience

7 DRUG INTERACTIONS

8 USE IN SPECIFIC POPULATIONS

If irritation develops, mometasone furoate cream should be discontinued and appropriate therapy

instituted. Allergic contact dermatitis with corticosteroids is usually diagnosed by observing a

failure to heal rather than noting a clinical exacerbation as with most topical products not

containing corticosteroids. Such an observation should be corroborated with appropriate

diagnostic patch testing.

If concomitant skin infections are present or develop, an appropriate antifungal or antibacterial

agent should be used. If a favorable response does not occur promptly, use of mometasone

furoate cream should be discontinued until the infection has been adequately controlled.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates

observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials

of another drug and may not reflect the rates observed in clinical practice.

In controlled clinical trials involving 319 subjects, the incidence of adverse reactions associated

with the use of mometasone furoate cream was 1.6%. Reported reactions included burning,

pruritus, and skin atrophy. Reports of rosacea associated with the use of mometasone furoate

cream have also been received. In controlled clinical trials (n=74) involving pediatric subjects 2

to 12 years of age, the incidence of adverse experiences associated with the use of mometasone

furoate cream was approximately 7%. Reported reactions included stinging, pruritus, and

furunculosis.

The following adverse reactions were reported to be possibly or probably related to treatment

with mometasone furoate cream during clinical trials in 4% of 182 pediatric subjects 6 months to 2

years of age: decreased glucocorticoid levels, 2; paresthesia, 2; folliculitis, 1; moniliasis, 1;

bacterial infection, 1; skin depigmentation, 1. The following signs of skin atrophy were also

observed among 97 subjects treated with mometasone furoate cream in a clinical trial: shininess, 4;

telangiectasia, 1; loss of elasticity, 4; loss of normal skin markings, 4; thinness, 1; and bruising, 1.

Because adverse reactions are reported voluntarily from a population of uncertain size, it is not

always possible to reliably estimate their frequency or establish a causal relationship to drug

exposure.

Postmarketing reports for local adverse reactions to topical corticosteroids include irritation,

dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis,

allergic contact dermatitis, secondary infection, striae, and miliaria. These adverse reactions may

occur more frequently with the use of occlusive dressings.

Postmarketing reports for ophthalmic adverse reactions to topical corticosteroids include blurred

vision, cataracts, glaucoma, increased intraocular pressure, and central serous chorioretinopathy.

No drug-drug interaction studies have been conducted with mometasone furoate cream.

8.1 Pregnancy

8.3 Nursing Mothers

8.4 Pediatric Use

Teratogenic Effects Pregnancy Category C:

There are no adequate and well-controlled studies in pregnant women. Therefore, mometasone

furoate cream should be used during pregnancy only if the potential benefit justifies the potential

risk to the fetus.

Corticosteroids have been shown to be teratogenic in laboratory animals when administered

systemically at relatively low dosage levels. Some corticosteroids have been shown to be

teratogenic after dermal application in laboratory animals.

When administered to pregnant rats, rabbits, and mice, mometasone furoate increased fetal

malformations. The doses that produced malformations also decreased fetal growth, as measured

by lower fetal weights and/or delayed ossification. Mometasone furoate also caused dystocia and

related complications when administered to rats during the end of pregnancy.

In mice, mometasone furoate caused cleft palate at subcutaneous doses of 60 mcg/kg and above.

Fetal survival was reduced at 180 mcg/kg. No toxicity was observed at 20 mcg/kg. (Doses of 20,

60, and 180 mcg/kg in the mouse are approximately 0.01, 0.02, and 0.05 times the estimated

maximum clinical topical dose from mometasone furoate cream on a mcg/m basis.)

In rats, mometasone furoate produced umbilical hernias at topical doses of 600 mcg/kg and above.

A dose of 300 mcg/kg produced delays in ossification, but no malformations. (Doses of 300 and

600 mcg/kg in the rat are approximately 0.2 and 0.4 times the estimated maximum clinical topical

dose from mometasone furoate cream on a mcg/m basis.)

In rabbits, mometasone furoate caused multiple malformations (e.g., flexed front paws, gallbladder

agenesis, umbilical hernia, hydrocephaly) at topical doses of 150 mcg/kg and above

(approximately 0.2 times the estimated maximum clinical topical dose from mometasone furoate

cream on a mcg/m basis). In an oral study, mometasone furoate increased resorptions and caused

cleft palate and/or head malformations (hydrocephaly and domed head) at 700 mcg/kg. At 2800

mcg/kg most litters were aborted or resorbed. No toxicity was observed at 140 mcg/kg. (Doses at

140, 700, and 2800 mcg/kg in the rabbit are approximately 0.2, 0.9, and 3.6 times the estimated

maximum clinical topical dose from mometasone furoate cream on a mcg/m basis.)

When rats received subcutaneous doses of mometasone furoate throughout pregnancy or during

the later stages of pregnancy, 15 mcg/kg caused prolonged and difficult labor and reduced the

number of live births, birth weight, and early pup survival. Similar effects were not observed at

7.5 mcg/kg. (Doses of 7.5 and 15 mcg/kg in the rat are approximately 0.005 and 0.01 times the

estimated maximum clinical topical dose from mometasone furoate cream on a mcg/m basis.)

Systemically administered corticosteroids appear in human milk and could suppress growth,

interfere with endogenous corticosteroid production, or cause other untoward effects. It is not

known whether topical administration of corticosteroids could result in sufficient systemic

absorption to produce detectable quantities in human milk. Because many drugs are excreted in

human milk, caution should be exercised when mometasone furoate cream is administered to a

nursing woman.

Mometasone furoate cream may be used with caution in pediatric patients 2 years of age or older,

although the safety and efficacy of drug use for longer than 3 weeks have not been established.

Since safety and efficacy of mometasone furoate cream have not been established in pediatric

patients below 2 years of age, its use in this age group is not recommended.

In a pediatric trial, 24 atopic dermatitis subjects, of whom 19 subjects were age 2 to 12 years,

were treated with mometasone furoate cream once daily. The majority of subjects cleared within 3

8.5 Geriatric Use

10 OVERDOSAGE

11 DESCRIPTION

Mometasone Furoate Cream USP, 0.1% contains mometasone furoate, USP for topical use. Mometasone

furoate, USP is a synthetic corticosteroid with anti-inflammatory activity.

Chemically, mometasone furoate, USP is 9α,21-dichloro-11β,17-dihydroxy-16α-methylpregna-1,4-

diene-3,20-dione 17-(2-furoate), with the empirical formula C

H Cl

O , a molecular weight of

521.43 and the following structural formula:

were treated with mometasone furoate cream once daily. The majority of subjects cleared within 3

weeks.

Mometasone furoate cream caused HPA axis suppression in approximately 16% of pediatric

subjects ages 6 to 23 months, who showed normal adrenal function by Cortrosyn test before

starting treatment, and were treated for approximately 3 weeks over a mean body surface area of

41% (range 15% to 94%). The criteria for suppression were: basal cortisol level of ≤5 mcg/dL,

30-minute post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2

to 4 weeks after trial completion, available for 5 of the subjects, demonstrated suppressed HPA

axis function in 1 subject, using these same criteria. Long-term use of topical corticosteroids has

not been studied in this population [see Clinical Pharmacology (12.2)].

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk

than adults of HPA axis suppression and Cushing’s syndrome when they are treated with topical

corticosteroids. They are, therefore, also at greater risk of adrenal insufficiency during and/or

after withdrawal of treatment. Pediatric patients may be more susceptible than adults to skin

atrophy, including striae, when they are treated with topical corticosteroids. Pediatric patients

applying topical corticosteroids to greater than 20% of body surface are at higher risk of HPA

axis suppression.

HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain, and

intracranial hypertension have been reported in pediatric patients receiving topical

corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol

levels and an absence of response to ACTH stimulation. Manifestations of intracranial

hypertension include bulging fontanelles, headaches, and bilateral papilledema.

Mometasone furoate cream should not be used in the treatment of diaper dermatitis.

Clinical studies of mometasone furoate cream included 190 subjects who were 65 years of age

and over and 39 subjects who were 75 years of age and over. No overall differences in safety or

effectiveness were observed between these subjects and younger subjects, and other reported

clinical experience has not identified differences in responses between the elderly and younger

patients. However, greater sensitivity of some older individuals cannot be ruled out.

Topically applied mometasone furoate cream can be absorbed in sufficient amounts to produce

systemic effects [see Warnings and Precautions (5.1)].

Mometasone furoate, USP is a white to off-white powder, soluble in acetone and methylene chloride.

Each gram of Mometasone Furoate Cream USP, 0.1% contains: 1 mg mometasone furoate, USP in a

cream base of aluminum starch octenyl succinate (Dry-Flo Plus (Pure)), hexylene glycol, phospholipon

90 H, phosphoric acid, purified water, titanium dioxide, white petrolatum, and white wax.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

12.2 Pharmacodynamics

12.3 Pharmacokinetics

Like other topical corticosteroids, mometasone furoate has anti-inflammatory, antipruritic, and

vasoconstrictive properties. The mechanism of the anti-inflammatory activity of the topical

steroids, in general, is unclear. However, corticosteroids are thought to act by the induction of

phospholipase A inhibitory proteins, collectively called lipocortins. It is postulated that these

proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and

leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic

acid is released from membrane phospholipids by phospholipase A .

Studies performed with mometasone furoate cream indicate that it is in the medium range of

potency as compared with other topical corticosteroids.

In a study evaluating the effects of mometasone furoate cream on the HPA axis, 15 grams were

applied twice daily for 7 days to six adult subjects with psoriasis or atopic dermatitis. The cream

was applied without occlusion to at least 30% of the body surface. The results showed that the

drug caused a slight lowering of adrenal corticosteroid secretion [see Warnings and Precautions

(5.1)].

Ninety-seven pediatric subjects ages 6 to 23 months with atopic dermatitis were enrolled in an

open-label HPA axis safety study. Mometasone furoate cream was applied once daily for

approximately 3 weeks over a mean body surface area of 41% (range 15% to 94%). In

approximately 16% of subjects who showed normal adrenal function by Cortrosyn test before

starting treatment, adrenal suppression was observed at the end of treatment with mometasone

furoate cream. The criteria for suppression were: basal cortisol level of ≤5 mcg/dL, 30-minute

post-stimulation level of ≤18 mcg/dL, or an increase of <7 mcg/dL. Follow-up testing 2 to 4

weeks after stopping treatment, available for 5 of the subjects, demonstrated suppressed HPA axis

function in one subject, using these same criteria [see Use in Specific Populations (8.4)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING

Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room

Temperature]. Avoid excessive heat.

17 PATIENT COUNSELING INFORMATION

The extent of percutaneous absorption of topical corticosteroids is determined by many factors

including the vehicle and the integrity of the epidermal barrier. Studies in humans indicate that

approximately 0.4% of the applied dose of mometasone furoate cream enters the circulation after

8 hours of contact on normal skin without occlusion. Inflammation and/or other disease processes

in the skin may increase percutaneous absorption.

Long-term animal studies have not been performed to evaluate the carcinogenic potential of

mometasone furoate cream. Long-term carcinogenicity studies of mometasone furoate were

conducted by the inhalation route in rats and mice. In a 2-year carcinogenicity study in Sprague

Dawley rats, mometasone furoate demonstrated no statistically significant increase of tumors at

inhalation doses up to 67 mcg/kg (approximately 0.04 times the estimated maximum clinical topical

dose from mometasone furoate cream on a mcg/m basis). In a 19-month carcinogenicity study in

Swiss CD-1 mice, mometasone furoate demonstrated no statistically significant increase in the

incidence of tumors at inhalation doses up to 160 mcg/kg (approximately 0.05 times the estimated

maximum clinical topical dose from mometasone furoate cream on a mcg/m basis).

Mometasone furoate increased chromosomal aberrations in an in vitro Chinese hamster ovary cell

assay, but did not increase chromosomal aberrations in an in vitro Chinese hamster lung cell assay.

Mometasone furoate was not mutagenic in the Ames test or mouse lymphoma assay, and was not

clastogenic in an in vivo mouse micronucleus assay, a rat bone marrow chromosomal aberration

assay, or a mouse male germ-cell chromosomal aberration assay. Mometasone furoate also did not

induce unscheduled DNA synthesis in vivo in rat hepatocytes.

In reproductive studies in rats, impairment of fertility was not produced in male or female rats by

subcutaneous doses up to 15 mcg/kg (approximately 0.01 times the estimated maximum clinical

topical dose from mometasone furoate cream, on a mcg/m basis).

The safety and efficacy of the mometasone furoate cream for the treatment of corticosteroid-

responsive dermatoses were evaluated in two randomized, double-blind, vehicle-controlled

clinical trials, one in psoriasis and one in atopic dermatitis. A total 366 subjects (12 to 81 years of

age), of whom 177 received mometasone furoate cream and 181 subjects received vehicle cream,

were evaluated in these trials. Mometasone furoate cream or the vehicle cream were applied once

daily for 21 days.

The two trials showed mometasone furoate cream is effective in the treatment of psoriasis and

atopic dermatitis.

Mometasone furoate cream USP, 0.1% is a white to off-white, uniform and smooth cream and is

supplied in 15 g (NDC 16714-974-01) and 45 g (NDC 16714-974-02) tubes.

Manufactured for:

Northstar Rx LLC

Memphis, TN 38141.

Manufactured by:

Glenmark Pharmaceuticals Ltd.

Village: Kishanpura, Baddi Nalagarh Road,

Dist: Solan, Himachal Pradesh - 173205, India.

May 2019

Patient Information

Mometasone Furoate (moe-MET-a-sone-FYOOR-oh-ate)

Cream, 0.1%

Important information: Mometasone furoate cream is for use on skin only. Do not use mometasone

furoate cream in your eyes, mouth, or vagina.

What is Mometasone furoate cream?

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Inform patients of the following:

Use mometasone furoate cream as directed by the physician. It is for external use only.

Avoid contact with the eyes.

Advise patients to report any visual symptoms to their healthcare providers.

Do not use mometasone furoate cream on the face, underarms, or groin areas unless directed by

the physician.

Do not use mometasone furoate cream for any disorder other than that for which it was

prescribed.

Do not bandage or otherwise cover or wrap the treated skin area so as to be occlusive, unless

directed by the physician.

Report any signs of local adverse reactions to the physician.

Advise patients not to use mometasone furoate cream in the treatment of diaper dermatitis. Do not

apply mometasone furoate cream in the diaper area, as diapers or plastic pants may constitute

occlusive dressing.

Discontinue therapy when control is achieved. If no improvement is seen within 2 weeks, contact

the physician.

Do not use other corticosteroid-containing products with mometasone furoate cream without first

consulting with the physician.

Mometasone furoate cream is a prescription medicine used on the skin (topical) for the relief of

redness, swelling, heat, pain (inflammation) and itching, caused by certain skin problems in people

2 years of age and older.

It is not known if mometasone furoate cream is safe and effective for use in children under 2

years of age.

Mometasone furoate cream should not be used in children under 2 years of age.

It is not known if mometasone furoate cream is safe and effective for use in children longer than

3 weeks.

Do not use mometasone furoate cream if you are allergic to mometasone furoate or any of the

ingredients in mometasone furoate cream, 0.1%. See the end of this leaflet for a complete list of

ingredients in mometasone furoate cream.

Before using mometasone furoate cream, tell your healthcare provider about all your medical

conditions, including if you:

Tell your healthcare provider about all the medicines you take, including prescription and over-the-

counter medicines, vitamins, and herbal supplements.

Especially tell your healthcare provider if you take other corticosteroid medicines by mouth or use

other products on your skin or scalp that contain corticosteroids.

How should I use mometasone furoate cream?

What are the possible side effects of mometasone furoate cream?

Mometasone furoate cream may cause serious side effects, including:

The most common side effects of mometasone furoate cream include burning, itching, and thinning

of the skin (atrophy). These are not all the possible side effects of mometasone furoate cream.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-

FDA-1088.

have a skin infection at the site to be treated. You may also need medicine to treat the skin

infection.

are pregnant or plan to become pregnant. It is not known if mometasone furoate cream will harm

your unborn baby.

are breastfeeding or plan to breastfeed. It is not known if mometasone furoate cream passes into

your breast milk.

Use mometasone furoate cream exactly as your healthcare provider tells you to use it.

Apply a thin film of mometasone furoate cream to the affected skin area 1 time each day.

Tell your healthcare provider if the treated skin area does not get better after 2 weeks of

treatment.

Do not bandage, cover, or wrap the treated skin area unless your healthcare provider tells you

Mometasone furoate cream should not be used to treat diaper rash or redness. Do not apply

mometasone furoate cream in the diaper area if wearing diapers or plastic pants.

Avoid using mometasone furoate cream on the face, groin, or underarms (armpits).

Wash your hands after applying mometasone furoate cream.

Mometasone furoate cream can pass through your skin. Too much mometasone furoate cream

passing through your skin can cause your adrenal glands to stop working properly. Your

healthcare provider may do blood tests to check for adrenal gland problems.

Vision problems. Topical corticosteroids may increase your chance of developing vision

problems such as cataract and glaucoma. Tell your healthcare provider if you develop blurred

vision or other vision problems during treatment with mometasone furoate cream.

Skin problems. Skin problems may happen during treatment with mometasone furoate cream,

including allergic reactions (contact dermatitis) and skin infections at the treatment site. Stop using

mometasone furoate cream and tell your healthcare provider if you develop any skin reactions

such as pain, tenderness, swelling, or problems healing during treatment with mometasone furoate

cream.

How should I store mometasone furoate cream?

General information about the safe and effective use of mometasone furoate cream.

Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet.

Do not use mometasone furoate cream for a condition for which it was not prescribed. Do not give

mometasone furoate cream to other people, even if they have the same symptoms that you have. It may

harm them. You can ask your pharmacist or healthcare provider for information about mometasone

furoate cream that is written for health professionals.

What are the ingredients in mometasone furoate cream, 0.1%?

Active ingredient: mometasone furoate

Inactive ingredients: aluminum starch octenyl succinate (Dry-Flo Plus(Pure)), hexylene glycol,

phospholipon 90 H, phosphoric acid, purified water, titanium dioxide, white petrolatum, and white wax.

Manufactured for:

Northstar Rx LLC

Memphis, TN 38141.

Manufactured by:

Glenmark Pharmaceuticals Ltd.

Village: Kishanpura, Baddi Nalagarh Road,

Dist: Solan, Himachal Pradesh - 173205, India.

May 2019

This Patient Information has been approved by the U.S. Food and Drug Administration.

Package/Label Display Panel

NDC 16714-974-01

Mometasone Furaoate Cream USP, 0.1%

Store mometasone furoate cream at room temperature between 68°F to 77°F (20°C to 25°C).

Keep mometasone furoate cream and all medicines out of the reach of children.

MOMETASONE FUROATE

mometasone furoate cream

Product Information

Product T ype

HUMAN PRESCRIPTION DRUG

Ite m Code (Source )

NDC:16 714-9 74

Route of Administration

TOPICAL

Active Ingredient/Active Moiety

Ingredient Name

Basis of Strength

Stre ng th

MO METASO NE FURO ATE (UNII: 0 420 1GDN4R) (MOMETASONE - UNII:8 HR4QJ6 DW8 )

MOMETASONE FUROATE

1 mg in 1 g

Inactive Ingredients

Ingredient Name

Stre ng th

ALUMINUM STARCH O CTENYLSUCCINATE (UNII: I9 PJ0 O6 29 4)

HEXYLENE GLYCO L (UNII: KEH0 A3F75J)

HYDRO GENATED SO YBEAN LECITHIN (UNII: H110 9 Z9 J4N)

PHO SPHO RIC ACID (UNII: E4GA8 8 8 4NN)

WATER (UNII: 0 59 QF0 KO0 R)

TITANIUM DIO XIDE (UNII: 15FIX9 V2JP)

PETRO LATUM (UNII: 4T6 H12BN9 U)

WHITE WAX (UNII: 7G1J5DA9 7F)

Packag ing

NORTHSTAR RX LLC

#

Item Code

Package Description

Marketing Start Date

Marketing End Date

1

NDC:16 714-9 74-0 1

15 g in 1 TUBE; Type 0 : No t a Co mbinatio n Pro duct

0 9 /17/20 19

2

NDC:16 714-9 74-0 2

45 g in 1 TUBE; Type 0 : No t a Co mbinatio n Pro duct

0 9 /17/20 19

Marketing Information

Marke ting Cate gory

Application Numbe r or Monograph Citation

Marke ting Start Date

Marke ting End Date

ANDA

ANDA0 78 541

0 9 /17/20 19

Labeler -

NORT HST AR RX LLC (830546433)

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

Glenmark Pharmaceuticals Limited

6 76 1150 28

ANALYSIS(16 714-9 74) , MANUFACTURE(16 714-9 74)

Establishment

Name

Ad d re s s

ID/FEI

Busine ss Ope rations

Sterling Spa

338 6 8 9 70 3

API MANUFACTURE(16 714-9 74)

Revised: 5/2019

Similar products

Search alerts related to this product

View documents history

Share this information